Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6671865 | 0.96 | HRH3 (0.92) | HRH3HRH1SLC2A1 | |
| SCHEMBL6675509 | 0.93 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL14287568 | 0.92 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL14287578 | 0.92 | HRH3 (1.00) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL5093952 | 0.91 | HRH3 (0.97) | HRH3HRH1SLC2A1 | |
| Hydrochloric Acid SCHEMBL5101240 | 0.91 | HRH3 (0.97) | HRH3HRH1SLC2A1 | |
| SCHEMBL14287596 | 0.88 | HRH3 (0.93) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL5093983 | 0.87 | HRH3 (0.91) | HRH3HRH1 | |
| SCHEMBL6071218 | 0.86 | HRH3 (0.88) | HRH3HRH1 | |
| SCHEMBL14287582 | 0.85 | HRH3 (0.88) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089347-A1 | Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | US | disclosed |
| EP-1539704-A1 | SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018432-A1 | SUBSTITUTED AZEPINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089347-A1 | Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885SLC2A1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.